Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab maintenance interval optimization in moderate to severe chronic plaque psoriasis
2014-005339-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of secukinumab in psoriasis and plaque psoriasis (4 arms), sponsored by Novartis. Primary endpoint: PASI 90 response rate at Week 52 in Week 24 PASI 90 responders. Started Feb 2015; status: completed.
02
Drugs
secukinumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2014-005339-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005339-15.